8-K: Pluri Inc. Subsidiary Receives Notice of Termination for $4.2 Million U.S. Government Contract

Pluri Inc.'s subsidiary, Pluri Biotech Ltd., received a notice of termination from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) for a $4.2 million contract to develop PLX-R18 cell therapy.

Summary

• Pluri Inc. reported that its wholly-owned subsidiary, Pluri Biotech Ltd., received a formal notice of termination from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) for a contract.
• The termination, effective April 15, 2025, was for the government's convenience.
• The contract, announced on July 11, 2023, was a three-year, $4.2 million agreement to support the development of Pluri's PLX-R18 cell therapy as a potential treatment for Hematopoietic Acute Radiation Syndrome (H-ARS).
• The program involved collaboration with the U.S. Department of Defense Armed Forces Radiobiology Research Institute (AFRRI) and the Uniformed Services University of Health Sciences (USUHS).
• Pluri believes the termination may be due to broader federal budgetary and administrative adjustments affecting health-related agencies.
• The company is monitoring the situation and assessing potential implications for its ongoing programs.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the loss of a significant government contract, which impacts the company's research and development efforts.

Negatives

• Pluri Biotech Ltd. lost a $4.2 million contract with NIAID.
• The termination impacts the development of PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome (H-ARS).

Risks

• The termination of the contract could negatively impact Pluri's research and development efforts for PLX-R18 cell therapy.
• Broader federal budgetary adjustments may affect Pluri's other ongoing programs.
• The company faces uncertainty regarding the future funding and support for its research initiatives.

Future Outlook

The Company is monitoring these developments closely and will assess any potential implications for its ongoing programs.

Management Comments

• The Company believes that the termination of the contract may reflect broader federal budgetary and administrative adjustments that have recently affected multiple health-related agencies, including the National Institutes of Health.

Industry Context

Government funding for biotech research is subject to budgetary fluctuations, and contract terminations can occur due to shifting priorities or resource constraints. Companies relying on government grants and contracts face the risk of funding cuts or project cancellations.

Stakeholder Impact

• Shareholders may react negatively to the loss of the government contract.
• Employees involved in the PLX-R18 cell therapy program may be affected.
• The termination could impact the company's ability to develop and commercialize the PLX-R18 therapy.

Key Dates

Keywords

Pluri Inc., Pluri Biotech Ltd., NIAID, contract termination, PLX-R18, Hematopoietic Acute Radiation Syndrome, H-ARS, cell therapy, government funding, research and development